Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 425 of 6351
-
New drug masitinib could slow Alzheimer's decline
Disease control Not yet recruitingMasitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia). Study AB21004 will evaluate masitinib as an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate Alzh…
Phase 3 • Sponsor: AB Science • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Could a common supplement slow Alzheimer's? new trial aims to find out
Disease control Not yet recruitingThe goal of this clinical trial is to learn if tributyrin can help prevent or mitigate cognitive decline in individuals with mild Alzheimer's disease (AD). The trial will also examine the safety and effects of tributyrin on inflammation and gut microbiota. The main questions it a…
Phase 3 • Sponsor: Universidad de Almeria • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Engineered immune cells take on hard-to-treat breast cancer in new trial
Disease control Not yet recruitingThe purpose of this study is to find the biggest dose of HTR2 T cells that is safe, to see how long these cells last in the body, to learn the side effects, and to see if these cells are able to fight and kill HER2 expressing breast cancer. Patients eligible for this study have …
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Can CBD boost clozapine for Treatment-Resistant psychosis?
Disease control Not yet recruitingThe purpose of this trial is: * To investigate whether the response to clozapine treatment can be enhanced by adding cannabidiol (CBD), compared to placebo, in treatment resistant psychosis patients. * To confirm the safety of CBD in people with psychosis. The trial is a random…
Phase 3 • Sponsor: University of Oxford • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Magic mushroom compound could help veterans heal from PTSD
Symptom relief Not yet recruitingThis pilot study will examine the safety, tolerability, acceptability, and efficacy of combination psilocybin + psychotherapy to decrease PTSD symptoms. Participants will be randomized into two different treatment groups, allowing the investigators to directly compare PE augmente…
Phase 2 • Sponsor: Emory University • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
One-Time gene shot aims to mend broken hearts
Disease control Recruiting nowThis is a Phase 1, open-label, dose-escalation trial to characterize the safety, tolerability, and preliminary efficacy of RP-A701 following a single IV administration in high-risk adult patients with BAG3-DCM.
Phase 1 • Sponsor: Rocket Pharmaceuticals Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New surgery aims to stop debilitating arm swelling in breast cancer patients
Disease control Not yet recruitingLymphedema is a devastating complication of breast cancer surgery that decreases the quality of life of up to 40% of breast cancer survivors. Most lymphedema in breast cancer patients is because lymphatics shared between the axilla and the arm are sacrificed during axillary lymph…
Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Can zapping a few tumor spots extend cancer treatment success?
Disease control Not yet recruitingAdvancements in systemic antineoplastic therapies have led to improved overall survival rates for many solid tumors. However, metastatic disease remains a significant challenge and remains the leading cause of mortality for these patients. Additionally, there is a high attrition …
Sponsor: Chirec • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail aims to boost transplant success in elderly leukemia patients
Disease control Not yet recruitingAcute myeloid leukemia (AML) is a serious blood cancer that mainly affects older adults. For patients who achieve their first complete remission (CR1), allogeneic hematopoietic stem cell transplantation (HSCT) may provide a chance for long-term survival. However, relapse after tr…
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for tough lymphoma: Triple-Drug attack
Disease control Recruiting nowAn Open-Label, Single-Arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy of Azacitidine, Chidamide, and PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-Cell Lymphoma.
Early phase 1 • Sponsor: Second Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug combo aims to match standard care in colorectal cancer battle
Disease control Not yet recruitingThis is a randomized, double-blind, phase III clinical trial. The study aims to demonstrate that the treatment regimen of Enlituo® plus FOLFOX is equivalent to that of Erbitux® plus FOLFOX in participants with RAS/BRAF wild-type and MSS/pMMR locally advanced/metastatic colorectal…
Phase 3 • Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Stroke ambulance trial aims to cut disability from brain bleeds
Disease control Not yet recruitingMSU-ICH is a prospective, multicenter, Week-wise-randomized, open-label, blinded-endpoint (PROBE) clinical trial comparing ultra-early prehospital blood pressure lowering delivered by a Mobile Stroke Unit (MSU) with standard Emergency Medical Services (EMS) in patients with spont…
Sponsor: Xuanwu Hospital, Beijing • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to improve leukemia treatment before transplant
Disease control Recruiting nowThis clinical trial aims to compare the efficacy and safety of venetoclax-based consolidation therapy versus conventional consolidation chemotherapy (intermediate/high-dose cytarabine) in newly diagnosed adult patients with intermediate-risk acute myeloid leukemia (AML). Particip…
Phase 2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Could a Pre-Chemo drug shield bone marrow in head and neck cancer?
Disease control Not yet recruitingThis study is a prospective, single-arm, phase II clinical trial involving patients with advanced HNSCC receiving immunotherapy plus platinum-based dual-drug chemotherapy. It aims to evaluate the myeloprotective efficacy of administering trilaciclib prior to immunotherapy and pla…
Phase 2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Precision radiation meets new drugs in fight against brain metastases from melanoma
Disease control Not yet recruitingMelanoma is a type of cancer that can spread to the brain, making the disease harder to treat and worsening both survival and quality of life. In recent years, treatments have improved significantly thanks to advances in surgery, radiotherapy, immunotherapy, and targeted therapy…
Sponsor: European Institute of Oncology • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Heart scan AI could predict sudden cardiac death risk in common heart condition
Knowledge-focused OngoingHypertrophic cardiomyopathy (HCM) is one of the leading causes of sudden cardiac death (SCD), particularly in young and middle-aged individuals. Current arrhythmic risk stratification mainly relies on clinical and imaging-based models, including the ESC HCM Risk-SCD score and gui…
Sponsor: Centro Cardiologico Monzino • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
Could a metabolic modulator help people with type 1 diabetes use insulin better?
Disease control Recruiting nowThe study is a randomized, double-blind, parallel-group clinical trial to examine the effects of 24 weeks of oral AMX0035 (sodium phenylbutyrate + taurursodiol) versus placebo in 60 adults with Type 1 Diabetes (T1D) (n=30 per arm). Enrollment will be distributed equally between t…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
AI reads MRI scans to predict who will benefit from chemo
Diagnosis Recruiting nowThis study is a multicenter, prospective, observational cohort study to evaluate the predictive performance of pre-treatment DCE-MRI-based artificial intelligence (AI) models for neoadjuvant chemotherapy benefit in HR+/HER2- breast cancer. The study plans to enroll eligible HR+/H…
Sponsor: Fujian Cancer Hospital • Aim: Diagnosis
Last updated Jul 16, 2026 00:00 UTC
-
Can a tiny artery block stop brain bleeds from coming back?
Disease control OngoingThis international multicenter study evaluates the efficacy and safety of middle meningeal artery embolization (MMAE) using PVA particles or liquid embolic agents as a perioperative treatment to prevent the recurrence of chronic subdural hematoma (cSDH). All participating patient…
Sponsor: University Hospital Hradec Kralove • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a new PET tracer outsmart head and neck cancer metastases?
Diagnosis CancelledThe purpose of this study is to determine the diagnostic utility of 89Zr-panitumumab to identify metastatic lesion(s) in subjects with head and neck squamous cell carcinoma (HNSCC).
Phase 2 • Sponsor: Andrei Iagaru • Aim: Diagnosis
Last updated Aug 19, 2026 00:00 UTC